AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

12,614.00p
   
  • Change Today:
    -58.00p
  • 52 Week High: 15,316.00
  • 52 Week Low: 10,956.00
  • Currency: UK Pounds
  • Shares Issued: 1,551.04m
  • Volume: 116,168
  • Market Cap: £195,649m
  • RiskGrade: 123
  • Beta: 0.00

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

AstraZeneca Financials

Latest F'cast
Div Yield 1.9% 0.0%
Div Cover 2.1 3.0
Op Mrgn 23.4% 31.8%
ROCE 59.5%  
Latest F'cast
P/E 26.0 20.4
PEG 0.6 n/a
Pr/Revenue 4.5 3.8
Pr/Book 5.5  
Latest F'cast
Revenue 8.6% -19.1%
PBT 42.7% 21.9%
EPS 45.4% 54.4%
DPS 3.2% -41.3%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-21 37,417.00 (265.00) 8.00¢ 1,442.8 n/a -97% 287.00¢ 2.5%
31-Dec-22 44,351.00 2,501.00 212.00¢ 70.4 0.0 +2,550% 290.00¢ 1.9%
31-Dec-23 45,811.00 6,899.00 726.00¢ 19.4 0.1 +242% 290.00¢ 2.1%
31-Dec-24 54,073.00 8,691.00 454.00¢ 30.7 n/a -38% 310.00¢ 2.2%
31-Dec-25 58,739.00 12,402.00 660.00¢ 27.8 0.6 +45% 320.00¢ 1.7%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-26 63,219.16 20,115.27 761.61p 16.6 0.3 +54% 249.84p 0.0%
31-Dec-27 67,032.68 22,266.98 847.06p 15.0 1.3 +11% 264.79p 0.0%

Copyright © 2026 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

Trixeo approved in EU for asthma 23-Sep-2026 07:00 RNS
Klygefa recommended for EU approval by CHMP 21-Sep-2026 07:05 RNS
Enhertu recommended for approval in EU in early BC 21-Sep-2026 07:00 RNS

AstraZeneca ShareCast News

Astrazeneca secures two positive regulatory opin... 21-Sep-2026 ShareCast
Director dealings: Astrazeneca CEO raises stake 18-Sep-2026 ShareCast
Deutsche Bank upgrades Astrazeneca to 'hold' 15-Sep-2026 ShareCast

AstraZeneca Top Newspaper Links

Is now the right time to buy shares in AstraZene... 04-Aug-2026 Times
AstraZeneca shares fall on Bristol Myers Squibb ... 03-Aug-2026 Times
Fighting Frenchman shows us how as he ensures As... 30-Dec-2014 Daily Mail

Latest AstraZeneca Director Deals

Traded Action Notifier PriceAmountValue
14-Sep-26 Buy Pascal Soriot 12,102.00p 60,000 £7,261,199.80
14-Sep-26 Buy Dividends Aradhana Sarin 0.000p 73 £0.00
14-Sep-26 Buy Michel Demare 12,121.33p 2,500 £303,033.24

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 12,614.00p
Change Today -58.00p
% Change -0.46 %
52 Week High 15,316.00
52 Week Low 10,956.00
Volume 116,168
Shares Issued 1,551.04m
Market Cap £195,649m
Beta 0.00
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
94.66% below the market average94.66% below the market average94.66% below the market average94.66% below the market average94.66% below the market average
90.24% below the sector average90.24% below the sector average90.24% below the sector average90.24% below the sector average90.24% below the sector average
Price Trend
9.16% above the market average9.16% above the market average9.16% above the market average9.16% above the market average9.16% above the market average
45.45% above the sector average45.45% above the sector average45.45% above the sector average45.45% above the sector average45.45% above the sector average
Income
68.72% below the market average68.72% below the market average68.72% below the market average68.72% below the market average68.72% below the market average
Sector averageSector averageSector averageSector averageSector average
Growth
87.64% above the market average87.64% above the market average87.64% above the market average87.64% above the market average87.64% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 10
Buy 8
Neutral 6
Sell 0
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 06-Aug-26 19-Feb-26
Paid 08-Sep-26 23-Mar-26
Amount 106.00¢ 217.00¢

Trades for 23-Sep-2026

Time Volume / Share Price
08:58 10 @ 12,611.23p
08:58 58 @ 12,614.00p
08:58 56 @ 12,614.00p
08:58 55 @ 12,612.00p
08:58 60 @ 12,610.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page